Navigation Links
VIA Pharmaceuticals to Present at American Heart Association Scientific Sessions 2008
Date:9/15/2008

from current expectations include, but are not limited to:

-- our ability to obtain necessary financing;

-- our ability to control our operating expenses;

-- our ability to recruit and enroll patients for the FDG-PET clinical

trial;

-- failure to obtain sufficient data from enrolled patients that can be

used to evaluate VIA-2291, thereby impairing the validity or

statistical significance of our clinical trials;

-- our ability to successfully complete our clinical trials of VIA-2291

on expected timetables and the outcomes of such clinical trials;

-- complexities in designing and implementing cardiovascular clinical

trials using histological examinations, measurement of biomarkers,

medical imaging and atherosclerotic plaque bioassays;

-- the results of our clinical trials, including without limitation, with

respect to the safety and efficacy of VIA-2291;

-- the outcome of any legal proceedings;

-- our ability to obtain necessary FDA approvals;

-- our ability to successfully commercialize VIA-2291;

-- our ability to obtain and protect our intellectual property related to

our product candidates;

-- our potential for future growth and the development of our product

pipeline;

-- our ability to form and maintain collaborative relationships to

develop and commercialize our product candidates;

-- general economic and business conditions; and

-- the other risks described under Item IA "Risk Factors" in our Annual

Report on Form 10-K for the fiscal year ended December 31, 2007 on

file with the SEC.

All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth above. Forward-looking statements speak only as of the date they are made, and VIA u
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... -- Huntington Memorial Hospital is the first facility in ... replacement (TAVR), a minimally invasive replacement of heart valves. ... replace an aortic valve without a chest incision or ... The procedure is performed by a dedicated Huntington Hospital ... , MD, interventional cardiologist and Robbin Cohen , ...
(Date:3/26/2015)... March 26, 2015  OncoGenex Pharmaceuticals, Inc. (NASDAQ: ... clinical developments and announced fourth quarter and year ... Developments and Anticipated Near-term MilestonesCustirsen , ... to negotiate the termination of their collaboration and ... final termination agreement are ongoing. , Two ...
(Date:3/26/2015)... According to a new market research report ... Cryoablation, Others), Department (Interventional Radiology, Surgery, Oncology), Application (Liver ... Forecasts to 2019", published by MarketsandMarkets, the Tumor Ablation ... at a CAGR of 11.50% by 2019. ... through 195 pages and in-depth TOC on "Tumor Ablation ...
Breaking Medicine Technology:Huntington Memorial Hospital Performs Groundbreaking Minimally Invasive Replacement of Heart Valves 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 4OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 5OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 6OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 7OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 8Tumor Ablation Market Worth $462.0 Million by 2019 2Tumor Ablation Market Worth $462.0 Million by 2019 3Tumor Ablation Market Worth $462.0 Million by 2019 4
... that it will report its 2010 year-end earnings on Thursday, April ... an analyst and investor call at 9:00 AM EDT live via ... in the conference call within the U.S. and Canada, dial (866) ... (708) 290-1340. The conference ID is 58484489. ...
... Boston Scientific Corporation (NYSE: BSX ... (FDA) approval and launch of the ION™ Paclitaxel-Eluting ... drug-eluting stent technology.  The ION Stent System incorporates ... for coronary stenting and intended to improve the ...
Cached Medicine Technology:Boston Scientific Announces FDA Approval and U.S. Launch of ION™ Platinum Chromium Stent System 2Boston Scientific Announces FDA Approval and U.S. Launch of ION™ Platinum Chromium Stent System 3Boston Scientific Announces FDA Approval and U.S. Launch of ION™ Platinum Chromium Stent System 4Boston Scientific Announces FDA Approval and U.S. Launch of ION™ Platinum Chromium Stent System 5
(Date:3/28/2015)... LTW Cyber is an innovation hub for technology ... of addressing the needs of the global market for ... to grow while seeking collaborative opportunities with the other ... in LTW Cyber focus on secure application security, grounded ... and analyzing open source. As the hub matures, ...
(Date:3/27/2015)... March 27, 2015 The federal court ... allege the statin medication increases the risk that a ... Inc.’s Motion to Dismiss four individual cases that had ... Management Order issued in the U.S. District Court, District ... that the dismissals were warranted because the plaintiffs in ...
(Date:3/27/2015)... California (PRWEB) March 27, 2015 ... Entertainment’s EcoLuxe Lounge in the Stardust Penthouse on ... Debbie Durkin, Los Angeles’ leading sustainable product TV ... behind this unforgettable day-long event, which featured some ... and ecologically sound products and services. , “We ...
(Date:3/27/2015)... According to a recently published report series ... screw market in Europe is in decline due to ... segment. Price decreases are being seen across the entire ... the total European trauma device market, continued pricing pressure ... year after year. , “Such price drops are ...
(Date:3/27/2015)... According to Health Day , on March 6th, ... (NAS) are causing alarm for Florida officials. Infants born ... a month of their lives- and can experience seizures, ... condition is precipitated by drug use during pregnancy. Unfortunately, ... medically assisted drug treatment) will also inflict NAS on ...
Breaking Medicine News(10 mins):Health News:Canadian Cybersecurity Ventures Globalize as a Collective 2Health News:Canadian Cybersecurity Ventures Globalize as a Collective 3Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 2Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 3Health News:Choices Recovery Releases 'Salute to the Oscars' EcoLuxe Lounge Compilation Video 2Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 2Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 3Health News:In Florida Only 10% of Pregnant Mothers Are Referred to Drug Rehab Despite Testing Positive for Narcotics 2
... , MONDAY, March 7 (HealthDay News) -- Sleep tight, but ... message of a new survey that suggests many Americans might ... bedtime in front of the electronic glow of a television, ... exposure to bright light before bed disrupts sleep. But some ...
... , MONDAY, March 7 (HealthDay News) -- Genetics ... -- where fear and stress are a fact of daily ... decline, new research warns. The culprit is a specific ... that while this gene is known to play a key ...
... , MONDAY, March 7 (HealthDay News) -- Young adults ... less likely to achieve the same level of education ... Improved medical care over the past 40 years has ... surviving into adulthood. However, they carry the burden of ...
... less treatment in the American health care system than their ... dose of empathy helps close racial gaps in pain treatment. ... ease the pain of members of their own race in ... at the University of Wisconsin-Madison. "I want to be ...
... identified a critical part of the process by which ... childhood infections, respiratory syncytial virus, causes disease. ... for RSV, which in 2005 was estimated to have ... among children under five worldwide. By analyzing samples ...
... tumor growth, and naturally mounts an anti-cancer defense. Dendritic ... present them to T cells, and those "primed" T ... cells. In recent years, researchers have attempted to capitalize ... namely, by generating a pool of tumor antigen-pulsed DCs ...
Cached Medicine News:Health News:Using Electronics Before Bed May Hamper Sleep 2Health News:Using Electronics Before Bed May Hamper Sleep 3Health News:Mix of Genetics and Stress Can Impair Mental Abilities 2Health News:Surviving Serious Childhood Illness Takes Toll Later: Study 2Health News:Surviving Serious Childhood Illness Takes Toll Later: Study 3Health News:New perspective diminishes racial bias in pain treatment 2Health News:Scientists find key mechanism of childhood respiratory disease 2Health News:Scientists find key mechanism of childhood respiratory disease 3
Light weight adjustable trial frame, adult...
Classic Trial Frames UB3 that has long set the standard....
Non Sterile surgical blade....
BD Beaver Cataract blade, 30.0 mm long x 2.2 mm wide, designed for ICCE and ECCE procedures, designed for ICCE and ECCE, sterile....
Medicine Products: